Core Insights - Inogen, Inc. reported an adjusted loss per share of 11 cents for Q3 2024, an improvement from a loss of 36 cents in the same quarter last year and better than the Zacks Consensus Estimate of a loss of 51 cents per share [1] - The company achieved revenues of 88.8millionforQ32024,reflectingayear−over−yearincreaseof5.813.9 million, while sales revenues increased by 10.2% to 74.9million[4]−Domesticbusiness−to−businesssalesroseby35.116.5 million, and international business-to-business sales increased by 26.2% to 32.3million[5]ProfitabilityandMargins−Inogen′sadjustedgrossprofitincreasedby20.144.6 million, with an adjusted gross margin expansion of 598 basis points to 50.2% [7] - Adjusted operating expenses rose by 3.2% year-over-year to 49.1million,withanadjustedoperatinglossof4.5 million compared to a loss of 10.5millionintheprioryear[8]FinancialPosition−ThecompanyendedQ32024withcashandcashequivalentsof105.7 million, up from 97.9millionattheendofQ12024,andhadnodebtonitsbalancesheet[9]−Cumulativenetcashprovidedbyoperatingactivitieswas8.9 million, a significant improvement from a net cash usage of 0.1millionayearago[9]GuidanceandOutlook−Inogenreviseditsrevenueoutlookforthefullyeartobetween329 million and 331million,indicatinggrowthof4−5325 million to $330 million [10] - The company recently launched the Inogen Rove 4 Portable Oxygen Concentrator in the U.S. market, which is expected to positively impact future performance [11]